Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2025 07:45 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June ...
June 26, 2025 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

SOLANA BEACH, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
June 11, 2025 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Reverse Stock Split

SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
June 05, 2025 09:00 ET | Source: Artelo Biosciences

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
June 02, 2025 09:00 ET | Source: Artelo Biosciences

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression

SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
May 13, 2025 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
April 28, 2025 08:45 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 31, 2025 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 03, 2025 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
February 14, 2025 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...